← All trials
NCT01257672
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2011
- Primary completion
- Nov 1, 2013
- Completion date
- Nov 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 356
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of TriesteLead sponsor
- University of TriesteStudy chair
- Agenzia Italiana del FarmacoCollaborator
- University of TriesteReponsible party - principal investigator
- Mario Negri InstituteStudy director
- Mario Negri InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.